drugset / Trial / NCT07044349
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules. Approximately 72 patients will be included in this study.
Timeline
- Start
- 2025-09
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epothilone D | Small molecule | 35 mg/m2 | — |
| Subject | Epothilone D | Small molecule | 40 mg/m2 | — |
| Subject | Epothilone D | Small molecule | 50 mg/m2 | — |
| Subject | Epothilone D | Small molecule | 75 mg/m2 | — |